Shionogi & Co., Ltd. (FRA:SH0)
Germany · Delayed Price · Currency is EUR | Market Cap | 16.22B +31.5% |
| Revenue (ttm) | 2.53B +1.9% |
| Net Income | 1.06B +15.5% |
| EPS | 1.24 +15.7% |
| Shares Out | n/a |
| PE Ratio | 15.32 |
| Forward PE | n/a |
| Dividend | 0.39 (2.15%) |
| Ex-Dividend Date | Sep 29, 2025 |
| Volume | n/a |
| Average Volume | 9 |
| Open | 18.20 |
| Previous Close | 17.80 |
| Day's Range | 18.20 - 18.20 |
| 52-Week Range | 12.60 - 19.40 |
| Beta | n/a |
| RSI | 54.12 |
| Earnings Date | May 8, 2026 |
About Shionogi &
Shionogi & Co., Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan and internationally. The company was formerly known as Shionogi Shoten Co., Ltd. and changed its name to Shionogi & Co., Ltd. in 1943. The company was founded in 1878 and is headquartered in Osaka, Japan. [Read more]
Financial Performance
In fiscal year 2025, Shionogi &'s revenue was 438.27 billion, an increase of 0.73% compared to the previous year's 435.08 billion. Earnings were 170.44 billion, an increase of 5.19%.
Financial numbers in JPY Financial StatementsNews
Shionogi Announces First Patients Enrolled in Global Phase 2 Clinical Trial in Adults with Late-Onset Pompe Disease
OSAKA, Japan--(BUSINESS WIRE)--Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter “Shionogi”) announced the first patients were enrolled in Espr...
Japan's Shionogi boosts ViiV stake to 21.7% as Pfizer exits
Japan's Shionogi & Co said on Tuesday it would pay $2.13 billion for new shares in joint venture ViiV Healthcare, increasing its stake in the HIV drugmaker to 21.7% as U.S. drugmaker Pfizer exits its ...
Shionogi & Co., Ltd. and Maze Therapeutics, Inc. Announce Exclusive Worldwide License Agreement for MZE001, a Novel Therapeutic Candidate for the Treatment of Pompe Disease
OSAKA, Japan & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter “Shionogi”) and Maze Therapeutic...